secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001005286-25-000133
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary
--------------------------------------------------------------------------------

- New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.
- Bonus weighted 80% on Adjusted EBITDA and total revenue, 10% on individual objectives, 10% on company goals.
- Target bonus as % of transition-period base salary: CEO Paul Josephs 100%, CFO Ryan Lake 60%, Chief Legal Tom Salus 50%.
- Maximum payout capped at 200% of target level for financial goals; minimum Adjusted EBITDA threshold applies.
- CY 2025 plan replaces the prior FY 2026 Bonus Plan terminated due to the fiscal year change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000133/0001005286-25-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000133/lfcr-20250922.htm
  HTML page:      https://secwatch.observer/filing/0001005286-25-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer